These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
12. The potential use of PPARalpha agonists as immunosuppressive agents. Cunard R Curr Opin Investig Drugs; 2005 May; 6(5):467-72. PubMed ID: 15912959 [TBL] [Abstract][Full Text] [Related]
13. The importance of recognizing and treating low levels of high-density lipoprotein cholesterol: a new era in atherosclerosis management. Cardenas GA; Lavie CJ; Cardenas V; Milani RV; McCullough PA Rev Cardiovasc Med; 2008; 9(4):239-58. PubMed ID: 19122582 [TBL] [Abstract][Full Text] [Related]
15. Anti-atherogenic properties of fibrates may be largely due to their anti-inflammatory effects. Ye HJ; Zhao SP Med Hypotheses; 2006; 66(3):495-500. PubMed ID: 16289368 [TBL] [Abstract][Full Text] [Related]
16. [Molecular mechanism of action of the fibrates]. Fruchart JC; Duriez P; Staels B J Soc Biol; 1999; 193(1):67-75. PubMed ID: 10851558 [TBL] [Abstract][Full Text] [Related]
17. Effects of fenofibrate on inflammatory cytokines and blood pressure in patients with hypertriglyceridemia. Ye P; Li JJ; Su G; Zhang C Clin Chim Acta; 2005 Jun; 356(1-2):229-32. PubMed ID: 15936324 [No Abstract] [Full Text] [Related]
18. The treatment of dyslipidemia--what's left in the pipeline? Rau O; Zettl H; Popescu L; Steinhilber D; Schubert-Zsilavecz M ChemMedChem; 2008 Feb; 3(2):206-21. PubMed ID: 17963209 [TBL] [Abstract][Full Text] [Related]
19. The value of C-reactive protein as a marker of systemic inflammation in stable chronic obstructive pulmonary disease. Karadag F; Kirdar S; Karul AB; Ceylan E Eur J Intern Med; 2008 Mar; 19(2):104-8. PubMed ID: 18249305 [TBL] [Abstract][Full Text] [Related]
20. Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome? Barter PJ; Rye KA Arterioscler Thromb Vasc Biol; 2008 Jan; 28(1):39-46. PubMed ID: 17717290 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]